References
- Reid T. Choosing GLP-1 receptor agonists or DPP-4 inhibitors: weighing the clinical trial evidence. Clin Diabetes. 2012; 30: 3–12.
- Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. UpToDate [homepage on the Internet]. c2013. Available from: http://www.uptodate.com/contents/glucagon-like-peptide-1-based-therapies-for-the-treatment-of-type-2-diabetes-mellitus
- Unger J. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm. J Am Osteopath Assoc. 2011; 111(2 Suppl 1): eS2-eS9.
- Gallwitz B. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Handb Exp Pharmacol. 2011 (203): 53–74.
- Amod A, Ascott-Evans BH, Berg GI, et al. The 2012 SEMDSA guideline for the management of type 2 diabetes (revised). JEMDSA. 2012; 17(1): S1–S94.
- Monthly Index of Medical Specialities. Haymarket Media Group, 2013.
- Byetta® package insert; 2008.
- Recent advances in GLP-1 receptor agonists in the treatment of type 2 diabetes mellitus: a conference report from the 68th Scientific Sessions of the American Diabetes Association. Medscape [homepage on the Internet]. c2013. Available from: http://www.medscape.org/viewarticle/579731Accessed23/01/2013